PMC9807344_01
Contrast-enhanced CT images of representative lung and liver metastases before starting Axitinib.
IJU5-6-41-g001.jpg
PMC9807344_01_IJU5-6-41-g001.jpg
iju512545-fig-0002
Chest and abdominal pelvic contrast-enhanced CT demonstrated multiple lung metastases in both lungs, and multiple metastatic foci with a ring-shaped contrast effect were seen in the liver (Fig. 2).
The course of liver metastases treated with sunitinib by contrast-enhanced CT. (a) Before starting Sunitinib (b) 5 months later: The ring contrast effect was no longer seen and the tumor diameter markedly decreased. (c) 16 months later: Tumor had continued to shrink. (d) 22 months later: Tumor response was maintained.
IJU5-6-41-g002.jpg
PMC9807344_01_IJU5-6-41-g002.jpg
iju512545-fig-0003
Thereafter, because of the worsening of the retroperitoneal abscess, the dose of sunitinib was reduced to 12.5 mg, which does not cause any major health problems, and PR is maintained 34 months after sunitinib initiation (Fig. 3).